> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# MolecuLight Gains De Novo Marketing for Wound Imaging
- URL: https://www.fdaweb.com/moleculight-gains-de-novo-marketing-for-wound-imaging/
- Published: 2018-08-14T12:00:00.000Z
- Updated: 2026-09-15T00:25:40.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5142105

FDA has granted MolecuLight de novo classification allowing marketing of its wound fluorescence imaging device, the MolecuLight i:X, which is intended to digitally capture and document fluorescence information from wounds and surrounding tissue using still images and videos in real-time. The handheld device is designed for use at the point-of-care, and has no requirement to use contrast agents, the company says. It also allows clinicians to view and digitally record images of a wound, and view and digitally record images of fluorescence emitted from the a wound when exposed to an excitation light.